STOCK TITAN

Acurx Pharmaceuticals Inc - ACXP STOCK NEWS

Welcome to our dedicated news page for Acurx Pharmaceuticals (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acurx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acurx Pharmaceuticals's position in the market.

Rhea-AI Summary
Acurx Pharmaceuticals announces efficacy results from the Phase 2 clinical trial of ibezapolstat for the treatment of C. difficile Infection (CDI). The clinical cure rate is 96% in 26 patients. Ibezapolstat was well-tolerated with no serious adverse events. The company plans to advance to Phase 3 and has previously received FDA Qualified Infectious Disease Product and Fast-Track Designation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.05%
Tags
-
Rhea-AI Summary
Acurx Pharmaceuticals will discuss its Q3 2023 financial results on November 14, 2023. The conference call will provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
-
Rhea-AI Summary
Acurx Pharmaceuticals presents scientific posters and podium presentations on ibezapolstat at two conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.85%
Tags
none
Rhea-AI Summary
Acurx Pharmaceuticals discontinues Phase 2b trial of ibezapolstat due to success. High rates of clinical cure observed without safety concerns. Phase 3 trials to be expedited.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
-
Rhea-AI Summary
Acurx Pharmaceuticals is enrolling in a Phase 2b trial for C. difficile infection and nearing its goal of 36 patients. They have received FDA QIDP and Fast-Track Designation. The company's preclinical pipeline targets gram-positive bacterial infections. No concrete business takes affecting stock price were found.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
Rhea-AI Summary
Acurx Pharmaceuticals to present at H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
conferences
Rhea-AI Summary
Acurx Pharmaceuticals announced financial and operational results for Q2 2023. The company continues to enroll patients in its Phase 2b clinical trial for C. difficile infection. Acurx anticipates completing enrollment of the required patients in the coming months. The company also announced upcoming presentations at two scientific conferences. Acurx is continuing its R&D collaboration with Leiden University Medical Center. The company's application for a non-dilutive grant was not approved by CARB-X. Second quarter financial results show a cash position of $9.1 million and increased R&D and G&A expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.39%
Tags
-
Rhea-AI Summary
Acurx Pharmaceuticals, Inc. will discuss its second quarter 2023 financial results on August 14, 2023. The clinical stage biopharmaceutical company is developing a new class of antibiotics for difficult-to-treat bacterial infections. The conference call will be hosted by President and CEO David P. Luci and CFO Robert G. Shawah.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
-
Rhea-AI Summary
Acurx Pharmaceuticals will present at the Emerging Growth Conference on July 12, 2023. The presentation will provide an update on the company's current initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
conferences acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences
Acurx Pharmaceuticals Inc

Nasdaq:ACXP

ACXP Rankings

ACXP Stock Data

26.16M
13.35M
15.26%
11.63%
2.14%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Staten Island